

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No. 70009590-0015

02/16/99  
U.S. PRO  
JC618

02/16/99  
U.S. PRO  
JC135  
09/251133

Assist. Commissioner for Patents  
BOX PATENT APPLICATION - FEES  
Washington, D.C. 20231

## NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor(s): Girish V. Shah

For (title): NEUROENDOCRINE MARKER OF PROSTATE CANCER AND METHOD FOR PRODUCING SAME

## 1. Type of Application

This new application is for a(n)

Original  
 Design  
 Divisional  
 Continuation  
 Continuation-in-part (CIP)

## 2. Benefit of Prior U.S. Application(s)

The new application being transmitted claims the benefit of prior U.S. provision application(s), Serial No. 60/074,809 filed February 17, 1998.

## CERTIFICATION UNDER 37 CFR §1.10

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date February 16, 1999 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EM 004 538 563 US addressed to the: Assist. Commissioner for Patents, BOX PATENT APPLICATIONS - FEES, Washington, D.C. 20231

Lori Dunham

(Type or print name of person mailing paper)

(Signature of person mailing paper)

**3. Papers Enclosed Which Are Required For Filing Date Under 37 CFR §1.53(b) (Regular) or 37 CFR 1.153 (Design) Application**

28 Pages of specification  
2 Pages of claims  
1 Pages of Abstract  
21 Sheets of drawing (Figures 1-19)  
[ ] formal  
[X] informal  
[X] in triplicate

**4. Additional papers enclosed**

[ ] Preliminary Amendment  
[ ] Information Disclosure Statement  
[ ] Form PTO-1449  
[ ] Citations  
[ ] Declaration of Biological Deposit  
[ ] Special Comments  
[ ] Other

**5. Declaration of oath**

[ ] Enclosed  
executed by (*check all applicable boxes*)  
[X] inventor(s)  
[ ] legal representative of inventor(s) 37 CFR §1.42 or 1.43  
[ ] joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.  
[ ] this is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached.  
[X] Not Enclosed. Will be submitted under separate cover.

## 6. Inventorship Statement

The inventorship for all the claims in this application are:

The same

or

Are not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,  
 is submitted  
 will be submitted.

## 7. Language

English

non-English

the attached translation is a verified translation. 37 CFR §1.52(d).

## 8. Assignment

An assignment of the invention to UNIVERSITY OF KANSAS MEDICAL CENTER  
 is attached  
 will follow  
 filed in prior application at Reel/Frame 9002/0202, recordation date February 17, 1998.

## 9. Certified Copy

Certified copy(ies) of the application(s):

(Country)	(Appln. No.)	(Filed)

from which priority is claimed

is(are) attached  
 will follow.

**10. Fee Calculation****A. [X] Regular application**

CLAIMS AS FILED						
	Number Filed	Number Extra	Rate	BasicFee		
<b>Total</b>				<b>\$760.00</b>		
Claims	5 - 20=	0	X \$ 18.00	\$ 0.00		
Independent Claims	1 - 3=	0	X \$ 78.00	\$ 0.00		
Multiple dependent claim(s), if any		0	\$260.00	\$ 0.00		

- Amendment cancelling extra claims enclosed
- Amendment deleting multiple dependencies enclosed
- Fee for extra claims is not being paid at this time

Filing Fee Calculation \$760.00

**B. [ ] Design application  
(\$330.00 - 37 CFR §1.16(f))**

Filing Fee Calculation \$

**11. Small Entity Statement(s)**

- Verified Statement(s) that this is a filing by a small entity under 37 CFR §1.9 and 1.27 is(are) attached. (Copy of Verified Statement filed in provisional application, Serial No. 60/074,809 filed February 17, 1998.)
- Verified Statement(s) that this is a filing by a small entity under 37 CFR §1.9 and 1.27 will follow.

Filing Fee Calculation \$380.00

**12. Fee Payment Being Made At this Time**

Not Enclosed

No filing fee is to be paid at this time.

Enclosed

<input checked="" type="checkbox"/> basic filing fee	\$380.00
<input type="checkbox"/> recording assignment (\$40.00; 37 CFR §1.21(h)(1))	\$ 0.00
<input type="checkbox"/> petition fee for filing by other than all the inventors or person on behalf of the inventor where inventor refused to sign or cannot be reached. (\$130.00; 37 CFR §1.47 and 1.17(h))	\$ 0.00
<input type="checkbox"/> for processing an application with a specification in a non-English language. (\$130.00; 37 CFR §1.52(d) and 1.17(k))	\$ 0.00
<input type="checkbox"/> processing and retention fee (\$130.00; 37 CFR §1.53(d) and 1.21(l))	\$ 0.00

**Total fees enclosed** **\$380.00**

**13. Method of Payment of Fees**

check in the amount of \$\_\_\_\_\_

charge Account No. 19-3140 in the amount of \$ 380.00. A duplicate of this transmittal is attached.

**14. Authorization to Charge Additional Fees**

The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. \_\_\_\_\_:

37 CFR §1.16 (filing fees)

37 CFR §1.16 (presentation of extra claims)

37 CFR §1.16(e) (surcharge for the filing of the basic filing fee and/or declaration on a date later than the filing date of the application)

37 CFR §1.17 (application processing fees)

37 CFR §1.18 (issue fee at or before mailing of Notice of Allowance, 37 CFR §1.311(b)).

Please charge any deficiency in the fees enclosed herewith to Deposit Account No. 19-3140. Two duplicate copies of this transmittal letter are enclosed.

**15. Instructions As to Overpayment**

credit Account No. \_\_\_\_\_  
 refund by check.



**SIGNATURE OF ATTORNEY**

Reg. No. 31,872

Tel. No. (312) 876-8192

David G. Rosenbaum  
SONNENSCHEIN, NATH & ROSENTHAL  
8000 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6404

**Incorporation by reference of added pages**

Plus Added Pages For New Application Transmittal Where Benefit of Prior U.S. Application(s) Claimed

Number of pages added \_\_\_\_\_

Plus Added Pages For Papers Referred To In Item 4 Above

Number of pages added \_\_\_\_\_

**Statement Where No Further Pages Added**

This transmittal ends with this page.

Applicant or Patentee: Girish V. ShahAttorney Docket No. 700095900005

Serial or Patent No.:

Filed or Issued: Filed February 17, 1998For: NEUROENDOCRINE MARKER OF PROSTATE CANCER AND METHOD FOR PRODUCING SAME

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) AND 1.27(d) - NONPROFIT ORGANIZATION)**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: University of Kansas Medical CenterADDRESS OF ORGANIZATION: 3901 Rainbow Boulevard, Kansas City, Kansas 66160-7702

## TYPE OF ORGANIZATION:

(X) UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION  
 ( ) TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3))  
 ( ) NONPROFIT SCIENTIFIC OR EDUCATION UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA

(NAME OF STATE \_\_\_\_\_)

(CITATION OF STATUTE \_\_\_\_\_)

( ) WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3)) IF LOCATED IN UNITED STATES OF AMERICA

( ) WOULD QUALIFY AS NON PROFIT SCIENTIFIC OR EDUCATION UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA

(NAME OF STATE \_\_\_\_\_)

(CITATION OF STATUTE \_\_\_\_\_)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office with regard to the invention entitled NEUROENDOCRINE MARKER OF PROSTATE CANCER AND METHOD FOR PRODUCING SAME by inventor(s) Girish V. Shah

described in:

(X) the specification filed herewith.  
 ( ) application serial no. \_\_\_\_\_, filed \_\_\_\_\_.  
 ( ) patent no. \_\_\_\_\_, issued \_\_\_\_\_.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern, or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). \*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)


NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

( ) INDIVIDUAL ( ) SMALL BUSINESS CONCERN ( ) NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: A.L. Chapman, Ph.D.TITLE IN ORGANIZATION: Vice Chancellor for Academic AffairsADDRESS OF PERSON SIGNING: 3901 Rainbow Boulevard, Kansas City, Kansas 66160-7702SIGNATURE: DATE 2-17-98

**NEUROENDOCRINE MARKER OF PROSTATE CANCER  
AND METHOD FOR PRODUCING SAME**

**RELATED APPLICATION**

This application is based on United States Provisional Application Ser. No. 60/074,809 filed February 17, 1998.

**FIELD OF THE INVENTION**

The present invention relates generally to markers for cancer diagnosis and treatment, and more specifically, to a novel neuroendocrine growth factor to diagnose and treat invasive and metastatic prostate cancer and other cancers that express this growth factor.

**BACKGROUND**

Prostatic carcinoma is the leading malignancy in human males in terms of incidence and the second leading cause of cancer deaths in men. While a majority of prostatic carcinomas remain dormant for a long period of time, a significant minority of them displays rapid growth and invasive characteristics. The mechanisms responsible for the latent growth of tumors in a majority of cases and for rapid progression in a minority of cases have not been identified. It has been suggested that tumors with greater neuroendocrine cell populations may display autonomous growth, androgen-independence and increased invasiveness. *See Cohen et al., Neuroendocrine Differentiation in Prostatic Adenocarcinoma and Its Relationship to Tumor Progression, CANCER 74:1899-1903 (1994); Huang et al., Relation Between Neuroendocrine Expression of Prostatic Carcinoma and Prognosis, CHUNG. HUA. I. HSUEH. TSA. CHIH. 74:23-5, 62 (1994); Kadmon et al., Elevated Plasma Chromogranin-A Concentrations in Prostatic Carcinoma, J. UROL. 146:358-61 (1991).*

The major therapeutic approach for the treatment of prostate cancer is androgen-deprivation through chemical means or surgical removal of the tumor. Indeed, patients with advanced prostatic carcinoma (PC) as well as experimental *in vitro* PC models respond largely to various methods of androgen deprivation such as orchiectomy, administration of estrogens, anti-androgens and analogs of gonadotropin-releasing hormone (LH-RH). However, a significant population of these individuals also exhibits tumor relapse in 18-36 months. Relapse and the subsequent spread of prostate cancer cells have been associated with androgen-insensitivity. Therefore, a possible cause of relapse, local invasion, and metastasis is the proliferation of androgen-insensitive clones. That is,

those cancer cells which require androgens for growth die when they are deprived of androgens during therapy, but those aggressive androgen-independent prostatic carcinoma cells ("AIPC cells") continue to proliferate even in the absence of androgens. Two areas of prostate cancer biology currently under intense investigation include: (1) the cause of relapse of prostate carcinoma in patients who initially respond to androgen deprivation treatments; and (2) the early detection of prostatic carcinomas that will become metastatic. Once the relapse occurs, few treatment options are available and eventually the patient dies from the disease. Continued proliferation of clonally derived AIPC tumor cells is believed to be the underlying cause of the relapse, as metastatic tumors are frequently found to be androgen-independent. Although AIPC cells are by definition independent from influence by androgens, there are neuroendocrine and other growth factors, which can stimulate their growth. Tumor cells are known to express distinct markers at the very early stage of transformation. Several tumor markers have been identified and have been used to identify either the presence of malignancy and/or the severity of the malignancy. For example, prostate-specific antigen (PSA) has been identified and used for the diagnosis of prostate cancer. Although PSA has been used as a marker for PC for several years, current evidence suggests that serum PSA levels: (1) do not always correlate with progression of the disease; (2) are not expressed in a small but significant number of aggressive PCs which therefore are undetected by PSA screening; and (3) do not predict the clinical nature of the tumor, i.e., even if the tumor is detected early, PSA screening does not predict whether the tumor will be dormant and therefore relatively harmless, or will be aggressive requiring immediate clinical intervention. Although PSA is used as a diagnostic marker for PC, neither PSA nor other serum markers can reliably identify the metastatic phenotype. Given the fact that not all prostate tumors secrete or express PSA, there is a critical need to develop other markers to identify metastatic phenotypes and PSA negative PC subtypes.

Substantial evidence exists suggesting the role of neuroendocrine growth factors in regulation of AIPC cells. For example, neuroendocrine factors such as bombesin and vasoactive intestinal polypeptide have been shown to influence the invasive behavior of prostate cancer cell lines. Other factors not necessarily regarded as exclusively neuroendocrine in origin, but secreted by neuroendocrine cells such as epidermal growth factor and somatostatin, have also been shown to influence either the invasive characteristics or growth of prostate cancer cell lines. Pindobind, a serotonin H1a receptor antagonist, has been shown to inhibit the growth of prostate cancer cell lines. In addition, foci of neuroendocrine differentiation have been demonstrated in between 47% and 100% of prostate cancers using a combination of sensitive argyrophil staining and

immunocytochemistry. Thus, it is likely that neuroendocrine factors play an important role in prostate cancer.

Grade of the cancer determines the severity of the cancer and varies from low to high grades. Low grade prostate tumor grows very slowly and often does not require any aggressive forms of therapy. However, high-grade prostate tumor grows and metastasizes aggressively and requires aggressive therapeutic intervention. Determination of the grade of prostate tumor is crucial for the choosing the right form of therapy. Present methods of determination of the grade of prostate cancer involve examination of the architecture of the prostate tumor in sections of biopsy. However, this method is prone to error due to the fact that there is considerable inter-observer variation leading to wrong diagnosis of the grade of the tumor. Determination of the grade of the tumor based on a biochemical marker rather than the visual observation of the architecture of the tissue would provide a better method for identifying the grade of the tumor. This has led to major efforts at identifying new biochemical markers for prostate cancer.

The present invention involves a novel neuroendocrine growth factor or marker (“NEM”) identified in cultured prostate cancer cells. A significantly higher number of binding sites for this novel NEM is present on membranes of prostatic cancer cells than on those of benign prostatic hypertrophy (BPH), a common benign enlargement of the prostate in older men. The ability to differentiate BPH from malignancy is highly important but cannot be effectively accomplished using PSA screening, the most commonly used method for detecting the presence of prostate cancer clinically. The limitations of PSA screening are overcome by screening patient blood for NEM which will identify metastatic prostate cancer, distinguish it from BPH, and can be used in excised tissues to identify the type of cancer and grade its degree of malignancy. Lastly, inhibition of NEM in turn decreases prostatic cancer growth, invasion and metastasis. As such, NEM antagonism offers new modes of therapy for prostate cancer. The data also shows that the expression of NEM in prostate cancer tissues increases with the grade of the cancer. While there is very little or no NEM expression of NEM in BPH (a non-cancerous condition) NEM expression can be seen in all prostate cancer tissues starting as early as the PIN stage, which is considered to be a precursor of invasive cancer. Hence the data shows that NEM is a good biochemical marker for prostate cancer.

## **SUMMARY OF THE INVENTION**

The invention describes a novel growth factor or marker (NEM) isolated from prostate cancer cells that induces the growth and invasion of prostate cancer cells and other cancer cells, and

is closely associated with the grade of prostate cancer. One mechanism by which NEM induces the growth of cancer cells is by binding to its receptor (NEM receptor) present on cancer cells which then induces growth and invasion. Blocking the interaction of NEM with its receptor by using an antibody directed against NEM or its receptor would inhibit the growth and invasion of these cancer cells thereby providing therapeutic benefits.

NEM is prepared by first subcloning the complementary DNA in a vector. The plasmid containing NEM cDNA is then transfected in prostate cancer cell line PC-3M cells, and after incubation and culturing, the expressed protein is obtained by affinity chromatography. Standard automated chemical synthesis and purification can also make the protein.

Polyclonal antibodies to NEM are prepared by injecting rabbits with antigen and removing a blood sample after the immune response has occurred. The immunoglobulin fraction of the serum is purified and used as the antiserum. More specific monoclonal antibodies are also prepared which can recognize a single antigenic determinant.

The inventive polyclonal and monoclonal antibodies and the novel probes are utilized in the detection of NEM in tissues and body fluids and grading of invasive and metastatic prostatic cancers and other cancers that exhibit enhanced production of NEM as well as those cancers which are PSA negative. This is successfully accomplished using immunohistochemistry, radioimmunoassay, enzyme-linked immunosorbent assay (ELISA), sandwich ELISA, EIA, fluoroimmunoassay, and chemiluminescence assay techniques, or other techniques used for the detection of peptides.

To create probes to detect complementary NEM mRNA in tissues by in-situ hybridization, cDNA for NEM is cloned into pGEM-T plasmids (Promega) and linearized with Sac II to make antisense strands and with PstI to make sense strand. The transcription reaction and digoxigenin 11-UTP (Boehringer Mannheim, Indianapolis, IN) labeling are performed with either SP6 (antisense) or T7 (sense) RNA polymerase provided in the riboprobe labeling kit (Promega). The labeled probes are digested with deoxyribonuclease (Boehringer), extracted with pheno-chloroform, and purified with TE Microselect-D G-50 spin columns (5 Prime-3Prime, Inc., Boulder, CO). The inventive antisense RNA (or nucleotide) probes against NEM can be used for detecting the presence of NEM RNA in prostatic and other cancer tissues that express NEM in order to determine the grade of the cancer. Primers based on the DNA sequence can also be used to determine the presence of disseminated prostatic and other cancer cells producing NEM to monitor the presence of metastasis.

The inventive NEM (or NEM receptor) antiserum and monoclonal antibodies inhibit the invasiveness of the disease and, thus, offer new forms of cancer therapy. For example, the polyclonal and monoclonal antibodies of the present invention are conjugated to chemotherapeutic agents and/or radionuclides to treat prostate cancer or other cancers that produce NEM or whose growth is enhanced by NEM. Gene therapy techniques and the preparation of an antagonist to prostatic NEM (or its receptor) can also be employed to treat the disease.

It is therefore a primary object of the present invention to provide a method for preparing NEM and NEM receptor from tissue-cultured prostatic carcinoma cells and from prostatic tissues and by chemical methods of synthesis and purification through the use of recombinant DNA methods.

It is another object of the present invention to provide a method for preparing the corresponding oligonucleotides, which are used as probes to detect NEM in mRNA in tissues by in-situ hybridization.

It is a further object of the present invention to provide a method for identifying unknown metastases and for the grading of prostatic carcinomas.

It is yet another object of the present invention to provide a method for detecting metastatic prostatic cancer as well as PSA-negative prostatic cancers by measuring NEM immunoreactivity in tissues and in human fluids.

It is a still further object of the present invention to provide a method for making NEM antibodies, which are then therapeutically administered to inhibit the growth invasion of prostatic carcinoma and other cancers whose growth is influenced by NEM.

It is yet another object of the present invention to use NEM and antibodies against NEM to the target radionuclides for detecting the presence of primary and secondary sites of prostate cancer.

Yet another object of the present invention is to use NEM, antibodies against NEM or NEM receptor to target cell-killing radionuclides or other cytotoxic agents to cancer cells that selectively bind NEM to preferentially kill these cells.

Another object of the present invention is to use NEM as a prophylactic or therapeutic vaccine whereby these molecules in conjunction with other immunostimulatory molecules stimulate an immune response against cancer cells expressing these molecules to kill these cells.

Alternatively, NEM antibodies generated in the body by these procedures will neutralize NEM thereby providing therapeutic benefit.

It is yet another object to use peptides (D or L form) or other small molecules that bind NEM in order to neutralize its growth and invasion-inducing action.

Further, another objective is to use antisense molecules, ribozymes and triplex molecules targeted against NEM to interfere with the synthesis of NEM to produce therapeutic benefits for cancer.

These and other objects, features and advantages of the present invention are more readily understood by those of ordinary skill in the art from the following more detailed description of the preferred embodiments taken with reference to the accompanying figures.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

FIG. 1 is a bar graph illustrating the effect of exogenously added prostatic NEM on DNA synthesis of an aggressive prostate cancer cell line, PC-3M.

FIG. 2 is a bar graph illustrating a dose-dependent relationship between the concentration of prostatic NEM and the invasiveness of PC-3M cells.

FIG. 3 is a bar graph illustrating a dose-dependent inhibition of growth of PC-3M cells by antibodies to prostatic NEM (dilution of 1:100).

FIG. 4 is a bar graph illustrating a dose-dependent inhibition of invasiveness of PC-3M cells by anti-NEM anti-serum.

FIG. 5 is a series of immunohistochemistry photographs of prostatic cancer tissue samples using antibodies to prostatic NEM, and illustrating the degree of malignancy correlating with an amount of NEM expression. FIG. 5a is prostate cancer tissue at a premalignant stage (PIN); FIG. 5b is of a moderate grade tumor; and FIG. 5c is of an aggressive, high-grade tumor.

FIG. 6 is a series of photographs of prostate epithelium tissue samples following in-situ hybridization using prostatic mRNA to illustrate the expression of NEM mRNA in: (a) BPH 1; (b) PIN 2; (c) low grade tumor 1; (d) moderate grade tumor 2; (e) high grade tumor 2; and (f) very aggressive tumor 1. The NEM mRNA is expressed only by blue stained cells (primarily basal cells).

FIG. 7 is a series of photographs of tissue samples following in-situ hybridization using prostatic NEM mRNA illustrating that the metastases are prostatic in origin in the liver (a); lymph node (b); and tonsil (c).

FIG. 8 is a graph illustrating the detection of prostatic NEM in correlation with PSA.

FIG. 9 is a schematic illustrating the mechanism of action pathway of an NEM-based cancer therapy as compared to an untreated cancer pathway.

FIG. 10 is a schematic of the mechanism of NEM-mediated proliferation and invasion of prostate cancer cells.

FIG. 11 is a schematic of NEM-based cell-targeted radiation therapy.

FIG. 12 is a schematic of NEM antibody-based therapeutic treatment for prostate cancer.

FIG. 13 is a series of photomicrographs depicting NEM selectively binding to prostate cancer cells.

FIG. 14 is series of photomicrographs of immunohisto-chemical detection of NEM in prostate cancer tissue sections, and detection of NEM in secondary sites of prostate cancer.

FIG. 15 is a series of photomicrographs of the expression of NEM in BPH and prostate cancer tissue sections.

FIG. 16 is a listing of cDNA Sequence ID 3 encoding NEM, and peptide Sequence IDs 6-8 depending on the reading frame utilized.

FIG. 17 is a listing of cDNA Sequence ID 4 encoding NEM, and peptide Sequence IDs 9-11 depending on the reading frame utilized.

FIG. 18 is a listing of cDNA Sequence ID 5 encoding NEM.

FIG. 19 is a listing of peptide Sequence ID 12 of NEM.

#### **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

As illustrated in Figs. 9 and 10, a mechanism of the proliferation and invasion of prostate cancer cells identified by Applicant relates to NEM's stimulation of a receptor on prostate cancer cells.

##### **1. *Preparation of Prostatic NEM***

Amino acid Sequence No. 1 was prepared by first subcloning the complementary DNA Sequence No. 2 in pRC vector (Invitrogen, San Diego, CA). The vector contains cytomegalovirus promoter upstream of the cloning site, and ensures high level expression of the cloned cDNA. The pRC plasmid containing NEM cDNA is then transfected in prostate cancer cell line PC-3M cells using Lipofectamine (Life Technologies, Inc., Gaithersburg, MD). In brief, PC-3M cells were plated at a density of 15,000 cells per well in a six-well culture plate and transfected 24 hours later with either the vehicle plasmid or the plasmids carrying cDNAs. Aliquots containing 2  $\mu$ g plasmid and 4 mg Lipofectamine in 1 ml serum-free, protein-free Dulbecco's Modified Eagle's medium (DMEM) were incubated for 45 minutes and added to culture wells. The transfection media was replaced with the complete medium 16 hours later. Two days later, the cells were cultured in selection medium (complete medium containing 400  $\mu$ g/ml of G418). Individual colonies of the

transfectants (NEM PC-3M) were selected after four weeks of culture, dispersed with trypsin/EDTA and propagated further into fresh flasks. The conditioned media was collected, the cells are lysed with a cocktail of detergents and the expressed protein in both these fractions was obtained by affinity chromatography using ProBond™ resin (as described by manufacturer's protocol, Invitrogen).

NEM isolated by Applicant and the purified DNA are being deposited with the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110.

Sequence IDs 2-5 (Sequence Listing and Figs. 16-18) are alternative cDNA sequences derived from the NEM peptide based on Applicant's research and within reasonable margins for error. Peptide Sequence IDs 1, 6-8, 9-11, 12 are alternative sequences based on the cDNA Sequence IDs depending on the reading frame employed to translate same.

## **2. Dose-Dependent Relationship of NEM on DNA Synthesis in PC-3M Cell Line**

Figure 1 illustrates the effect of exogenously added prostatic NEM on DNA synthesis of an aggressive prostate cancer (PC-3M) cell line. To obtain the results shown in FIG. 1, PC-3M cells were seeded at a density of 10,000 cells per well and incubated overnight in the complete medium. The cells were then washed with and incubated in serum-free medium containing the agents and 0.5  $\mu$ Ci of 3H-thymidine for 24 hours. At the end of incubation, the cells were washed three times with PBS-1  $\mu$ M thymidine and the incorporated radioactivity was determined in TCA-precipitable fraction. The results suggest that NEM stimulated 3H-thymidine incorporation in a dose-dependent fashion, and the increase in DNA synthesis produced by 10 nM or greater concentrations of NEM was significant. NEM also stimulates the growth of certain non-prostate cancer cells like certain bone-derived cell lines (OVCA-5), thereby extending the use of NEM in other cancers that produce or are stimulated by NEM.

## **3. Preparation of Anti-NEM Serum**

Two rabbits weighing about 2kg each were immunized by 240  $\mu$ g NEM(1-24)-KLH conjugate (NEM conjugated to keyhole limpet hemocyanin according to published procedures) in complete Freund's adjuvant. Booster doses of 120  $\mu$ g NEM(1-24)-KLH in incomplete Freund's adjuvant were given every 10 days after the primary injection. The rabbits were bled 10 days after the third booster dose, and antibody production was monitored using an enzyme-amplified enzyme-linked immunosorbent assay technique with NEM as the antigen on the solid phase. In this procedure, the cell lysate (50  $\mu$ l) from NEM-PC-3M cells was coated on ELISA plates. This served as the solid antigen phase. The anti-NEM rabbit serum was added to the wells at various

concentrations (dilutions of 10-100) as the solid antigen phase. The serum was then washed off with phosphate buffered saline and the solid phase was incubated with biotinylated Anti-rabbit gamma globulin. After incubation for 2 hours at room temperatures, the plates were washed and incubated with streptavidin-alkaline phosphatase (Sigma Chemical Co., St. Louis, MO). After thorough washing of the solid phase three times, the color reaction was initiated using BCIP-NBT substrate system (Bio-Rad, CA) according to the manufacturer's protocol.

#### **4. Stimulation of Invasiveness of PC-3M Cells by NEM**

Figure 2 illustrates the effect of NEM on in vitro invasion of PC-3M cells. The experiment used 3 well Matrigel invasion chambers (Becton Dickinson, Bedford, MA). Approximately 200,000 PC-3M cells were seeded in the upper chamber in RPMI 1640 medium containing 0.1% BSA (Sigma, St. Louis), 4 mM L-glutamine, 100 IU/ml penicillin G and 100 ug/ml streptomycin. The lower chamber medium contained chemoattractant medium consisting of 80% complete medium (RPMI 1640, 12% horse serum, 4% heat activated fetal calf serum, 4 mM L-glutamine, 100 IU/ml penicillin G and 100 mg/ml streptomycin). Different concentrations of NEM or conditioned media from NEM-PC3-M cells that express NEM (dilutions ranging from 1 to 5) were added to the upper chamber. The experiments were carried out for 72 hours. At the end of the incubation period the Matrigel was scraped off using cotton swabs and the top insert was fixed and stained using Diff Quick staining (Dade Diagnostics, Aguada, PR). The relative invasive potential was determined by normalizing for cell growth. This was done by plating 100,000 cells in six well dishes in chemoattractant medium and determining the relative growth of cells after 72 hours. The number of cells per 100 x field were expressed as mean +/- SEM.

Figure 2 demonstrates that NEM in a dose-dependent fashion significantly increases the invasiveness of PC-3M cells. The cells demonstrated a 70% increase from 0M to  $10^{-6}$ M NEM. All concentrations of NEM were significant in comparison to 0 CT for PC-3M. ( $P < 0.05$ ).

#### **5. Inhibition of Growth of PC-3M Cells With Anti-NEM Serum**

If NEM-induced DNA synthesis may influence proliferative activity of a prostate tumor and other cancer cells, then its immunoneutralization should reduce the growth. This hypothesis was tested by studying the rate of  $^3$ H-thymidine incorporation in PC-3M prostate cancer cells. The cells were treated either with non-immune antiserum or anti-NEM antiserum at a final dilution of 1:50. The results presented in FIG. 3 show that anti-NEM antiserum significantly inhibited DNA synthesis in PC-3M cells.

**6. Inhibition of Invasion of PC-3M Cells With Anti-NEM Serum**

Figure 4 illustrates the effect of the anti-NEM antiserum on invasion of PC-3M cells. The invasion assays were performed as described in conjunction with FIG. 3. Instead of stimulating PC-3M cells with NEM, the cells were treated with various concentrations anti-NEM serum. The parallel controls received equivalent amounts of non-immune rabbit serum. The results show that anti-NEM serum significantly reduced invasiveness of PC-3M prostate cancer cells and the decrease was significant at concentrations of 1:50 and 1:100.

**7. Detection of Prostatic NEM Peptide in PC Biopsies**

Figure 5 illustrates the detection of the peptide in PC biopsies (BPH-PIN-tumors of various grades). Paraffin-embedded sections were cut at 0.5 mm thickness. Paraffin sections were air-dried for 30 minutes, oven-dried, deparaffinized and rehydrated. Slides were microwaved on "high" with ChemMate antigen retrieval solution (BioTek, Santa Barbara). As a control for nonspecific staining, some of the anti-NEM serum was preabsorbed with 10  $\mu$ M NEM for one hour at 37°C prior to use. Non-absorbed and preabsorbed antisera were diluted at 1:70 in Antibody Dilution Buffer (BioTek). Avidin-biotin complex staining was carried out on a Tech Mate 1000 (BioTek) apparatus with ChemMate reagents. All slides were stained with ethyl green for 1 minute, cleared in butyl alcohol, rinsed in xylene and coverslipped. Cytoplasmic and nuclear staining of prostatic epithelium were scored on a scale from 0 (absent) to 4+ (strong and abundant) for a given cell type. Staining was scored as the sum of two components. First, the percent positive cells staining was determined as: <5% neg., 5-25% as 0.5, 35-50% as 1.0, 50-75% as 1.5 and 75-100% as 2.0. The intensity was then determined as: 0.5 for trace, 1.0 for low, 1.5 for moderate, and 2.0 for strong. Diagnosed Gleason grades were reassessed and compared with staining intensity in a paired correlation for n=20 cases. Among n=8 cases with both PIN and prostatic carcinoma, staining of these lesions was compared over the range of Gleason scores using a two-tailed t-test, assuming unequal variances. Also evaluated were staining of lymphocytes, urothelium, seminal vesicles and stroma. Statistical analysis used MS Excel 4.0 spreadsheet software. Significance was based on correlation coefficients with 2 degrees of freedom.

Staining data were also assessed by image analysis on 35 mm Kodak Ektachrome slides of benign, PIN and invasive cancer acini. Slides were scanned by a Polaroid SprintScan 35 scanner at 337 dots/inch and saved as JPEG images using an Adobe Photoshop program. The staining of cytoplasm of 50 cells per image was assessed using an NIH Image program, and the mean staining

for each image was calculated. The overall means  $\pm$  standard error were calculated for benign, PIN and invasive carcinoma acini and significance based on 2-tailed t-tests, assuming unequal variances.

A typical NEM staining profile obtained in PC specimens of different grades is presented in the photographs of FIGS. 5a-c. A total of 47 specimens were analyzed, and the results are presented in the following table.

	<u>Benign Acini</u>	<u>PIN Acini</u>	<u>Carcinoma</u>
number of cases analyzed	19	8	20
mean $\pm$ SEM	33.51 $\pm$ 3.01	48.62 $\pm$ 3.11*	65.25 $\pm$ 2.81*

NOTE: "SEM" means standard error of mean. "\*" means significantly different from benign acini.

Figure 6 illustrates the detection of the mRNA in PC biopsies (BPH, high grade PIN-tumors of various grades). The data clearly shows that while there is very little or no NEM expression in BPH tissues, it is clearly evident in high-grade PIN (prostatic, intraepithelial neoplasia) considered to be a pre-cancerous state. The data also clearly shows that NEM expression increases proportionally with the grade of cancer (as determined by Gleason score). Thus NEM seems to be a good biochemical marker for prostate cancer and also a good marker for determining the grade of prostate cancer. These experiments demonstrate the use of the immunohistochemical detection of NEM in prostate cancer biopsies and tissues for determining the grade of prostate cancer.

#### **8. Preparation of DNA Probes**

Partial complementary DNA (cDNA) for prostatic NEM was cloned into pGEM-T plasmid (Promega, Madison, WI) was linearized with Sac II to make antisense strand and with PstI to make sense strand. The transcription reaction and digoxigenin 11-UTP (Boehringer Mannheim, Indianapolis, IN) labeling were performed with either SP6 (antisense) or T7 (sense) RNA polymerase provided in the riboprobe labeling kit (Promega). The labeled probes were digested with deoxyribonuclease (Boehringer), extracted with pheno-chloroform, and purified with TE Microselect-D G-50 spin columns (5 Prime-3Prime, Inc., Boulder, CO).

#### **9. Detection of PC Using In-Situ Hybridization**

Slides of paraffinized prostate tissue sections were deparaffinized, and the ISH procedure was performed with the antisense mRNA probe as described by Panoskaltsis-Mortari and Bucy. As a negative control for ISH, the sense mRNA strand was substituted. The hybridization was performed overnight at 42°C. The washing of the sections was performed with 0.5%X SSC at

42°C. After the washing, the sections were incubated with mouse anti-digoxigenin antiserum conjugated to alkaline phosphatase. The color development of digoxigenin-coated alkaline phosphatase was carried out using BCIP-NBT substrate system (Bio-Rad) and the sections were counterstained with fast red. The results presented in the FIGS. 6a-f, 14-15 demonstrate the expression of NEM mRNA in prostate epithelium. Probes were also used to determine whether metastases were prostatic in origin in the liver, lymph node and tonsil (FIGS. 7a-c).

#### **10. Detection of NEM mRNA using RT-PCR**

NEM mRNA was detected in prostate cancer specimens as well as cell lines using RT-PCR technique according to published procedures. The primers used in this procedure were: agaacctgtgtgctggcta (forward) and catatactaccccggtta (reverse). The total RNA from the specimens was extracted using a Quiagen RNA extraction kit (Quiagen, CA) according to the manufacturer's protocols, reverse transcribed using reverse transcriptase and amplified using the previously described primers pair. The reaction mixture was then separated on 1% agarose gel, and the amplicon of approximate size of 350 bp was detected as predicted according to Sequence No. 1 in prostate cancer specimens and DU-145, MCF-7 and PC-3M cancer cell lines. NEM mRNA was also detected by RT-PCR in certain breast cancer tissues demonstrating that NEM may be a marker for other cancers also, particularly the ones that show a high degree of differentiation into the neuroendocrine-type cells like small lung carcinoma, certain pancreatic cancers, renal cancer, adrenomedullary carcinoma etc.

#### **11. Correlation of NEM Levels With PSA Levels**

Figure 8 illustrates the detection of the NEM antigen in serum samples and the correlation with PSA. Serum samples from patients with prostate cancer were obtained from the Department of Pathology and Laboratory Medicine at the University of Kansas Medical Center. Their PSA levels were determined at the Department of Pathology and they ranged from 13.2 - 2046 units. The samples were then processed for NEM radioimmunoassay (RIA) by standard antigen-antibody reaction. In this procedure, the serum samples were processed (for the removal of macromolecules) by precipitating w/acetate-ethanol and the supernatant was passed through a 0.5 ml Sephadex 625 column. The fractions containing the peptide were used for assays. The processed serum samples are incubated with anti-NEM serum for 24 hours at 4°C.  $I^{125}$ -labeled NEM is then added (approximately 30,000 cpm). The samples are then incubated for an additional 24 hours. At the end of incubation, the samples are treated with 4V of chilled ethanol, centrifuged and pellet is

counted for radioactivity. The values of NEM are derived by log-logit transformation of the data. The results are plotted as NEM levels (pg/ml) against PSA levels (units).

The results obtained following this procedure suggest a high degree of correlation between PSA levels and NEM levels in 8 of the 10 samples assayed. The degree of correlation was 0.772 and was statistically significant ( $p<0.01$ ). Furthermore, 2 samples that had low PSA levels exhibited significantly higher NEM levels. These preliminary results suggest that NEM may provide an additional paradigm for the detection of PC and other cancers that exhibit increased production of NEM. In addition, it can be useful in detecting PSA-negative PC cases.

## **12. Preparation of Vectors for RNA Synthesis and Antisense RNA, ribozymes and Aptamer Synthesis**

The NEM cDNA can be expressed in laboratory conditions or *in vivo* when the cDNA of the reported sequence or its antisense sequence or a ribozyme targeted against NEM mRNA or an aptamer sequence that binds NEM is cloned downstream of a promoter in a vector(s) which includes, but is not limited to, a viral vector or a plasmid vector under the control of a promoter where the promoters are chosen from a panel of eukaryotic promoters including, but not limited to, SV40 immediate early promoter, cytomegalovirus promoter, thymidine kinase promoter, Maloney murine leukemia virus long terminal repeat, U1 promoter, U6 promoter, tRNA promoter and VA promoter.

The NEM cDNA or its antisense (when transcribed in the reverse direction), ribozyme or aptamer can be formulated in a carrier for delivery to the prostate cancer cells and can be administered to patients through intravenous, intramuscular, subcutaneous injections or direct injections into the tumor tissue.

## **13. NEM Vaccine**

NEM expression cassette can also be used for immunotherapy. The NEM cDNA vaccine construct, which encodes for NEM can be directly inoculated into the host. The expression cassette will be under the control of a strong promoter such as a cytomegalovirus promoter. The transfected cells then become the production source of the NEM, and can sensitize immune cells against NEM. The sensitized immune cells become capable of destroying NEM producing endogenous prostate cancer cells. A similar approach using pCMV-PSA expression cassette has shown that a strong and persistent antibody response against PSA, a prostate protein, is observable for at least for six months after immunization. Alternate approaches may include injecting NEM after conjugation with other protein or glycoproteins to enhance their immune recognition or injecting these conjugates using

lipid formations. Use of the above methods in addition to eliciting cellular immunity could also induce humoral immunity (production of NEM specific antibodies). Such antibodies against NEM produced by the patients receiving NEM vaccine would neutralize the NEM produced and secreted by cancer cells, which would neutralize the growth and invasion-promoting action of NEM thereby providing additional therapeutic benefits.

**14. Preparation of Monoclonal, Single Chain, Phage-Display Selected, and In Vitro Evolved Antibodies to Prostatic NEM**

**A. Polyclonal Antibodies**

The antibody to NEM is produced when the NEM peptide of Sequence Nos. 1-6 or its precursor or fragments are conjugated to a large protein molecule by covalent linkage, mixed with an adjuvant and injected into either a rabbit, mouse or other host to generate an immune response. The serum or the spleen of the injected animal is harvested. The serum was found to contain immunoglobulin molecules generated in response to NEM, such molecules being capable of recognizing various antigenic sites on NEM and, thus, are called polyclonal antibodies. The serum is tested for the immune response whereas spleen cells are fused with tumor cells to generate hybridomas. The fused cells that secrete the antibody to NEM are thus immortalized and each cell secretes an immunoglobulin molecule that recognizes a single antigenic site of NEM. The antibodies can also be obtained by phage display when the expression vector (described above in "Preparation of Vector for RNA Synthesis") is injected into an animal.

More specifically, the antibody to NEM is generated when purified or synthetic NEM peptide (or its fragment, precursor or other modified form) is conjugated to key hole limpet hemocyanin by covalent linkage, mixed with an adjuvant and injected into either a rabbit, mouse or other host to generate an immune response (according to published procedure in Harlow, et al., ANTIBODIES: A LABORATORY MANUAL (1988) Cold Spring Harbor Laboratory, NY). The serum of the animal is then obtained. The serum contains immunoglobulin molecules generated in response to NEM injections which can recognize various antigenic sites on the NEM sequence. The IgC function of this serum is used for diagnostic purposes such as immunohistochemistry (as demonstrated by FIG. 5), immunoassays (as depicted in FIG. 8), and is also used for the immunoneutralization of NEM (as presented in FIGS. 3 and 4) or passive immunization of animal models.

## B. Monoclonal Antibodies

Purified NEM or a synthetic fragment of the peptide is conjugated to an immunogen like keyhole limpet hemocyanin or similar protein according to published procedures (Harlow, et al., *supra*). The conjugated immunogen is injected into a mouse and monoclonal antibodies are prepared according to published procedures. Several hybridoma clones secreting the murine monoclonal antibodies are isolated and the antibodies secreted by the cells are tested for their ability to bind to radioiodinated NEM. Generally, the hybridoma clones secreting antibodies with the highest affinity are selected. These antibodies are further tested for their ability to inhibit the growth and invasive properties of prostate cancer cells as described above.

The hybridoma culture is then scaled up in large bioreactors as is known in the art to produce large amounts of monoclonal antibodies. The antibody that is secreted into the cell culture media is purified using standard chromatographic methods and is used for diagnostic purpose or administered to prostate cancer patients as an aqueous formulation intravenously.

### **15. NEM Antibody for the Treatment of Prostate Cancer**

Currently, no effective therapies are available for the treatment of advanced prostate cancer. Surgical removal of the lesion, although effective if performed during the early stages of the disease, is not effective when the cancer has spread to distant locations. Accordingly, there is an unmet medical need for new drugs that are more effective than current alternatives.

An ideal therapeutic agent against prostate cancer should minimally possess three qualities: (1) It should interfere with the growth of prostate cancer cells; (2) it should prevent the spread of prostate cancer cells; and (3) it should be minimally toxic to normal cells.

Antibodies directed against NEM block the growth and the metastatic potential of prostate cancer cells grown in culture. As shown in Fig. 13, NEM selectively binds to NEM receptors on prostate cancer cells. The binding of the antibodies to NEM prevents NEM's interaction with its specific receptors, thereby inhibiting its growth promoting and metastatic properties. The pathway is illustrated in Fig. 12.

Based on the results discussed above, use of antibodies directed against NEM could be used as an effective therapy for prostate cancer. These antibodies could be administered alone or in conjunction with one of the currently available therapies. This type of combination therapy is being increasingly used for the treatment of a variety of diseases. Antibodies, particularly humanized monoclonal antibodies, or human antibodies, are gaining acceptance as therapeutics designed to block the action of various bioactive molecules involved in disease processes, and specifically for

the treatment of cancer. An example is the use of antibodies against HER2, a receptor protein that is expressed in high amounts in breast cancer and which mediates the action of certain peptide growth factors that induce breast cancer growth. These antibodies have shown efficacy in the treatment of breast cancer in animal models and in humans.

#### **16. *Humanized Monoclonal Antibodies Against NEM for the Treatment of Prostate Cancer***

Repeated administration of murine antibody (similar to the one mentioned above) to humans results in the generation of human anti-mouse antibody and eventual neutralization of the murine antibody. Humanization of the antibody or converting the murine antibody into a predominantly human antibody therefore reduces or prevents the formation of such human anti-mouse antibody. This technique involves cloning the variable regions of the murine antibody, which determines the specificity of the antibody towards an antigen into the constant regions of a human antibody. The variable region that determines the specificity towards an antigen is restricted to a few amino acids and hence the new hybrid antibody would be of predominantly human nature thus preventing the formation of antibodies against it once they are injected into humans. In addition, humanized antibodies have longer retention times in the body thereby allowing fewer doses of the antibody to the patient. Several such “humanized” monoclonal antibodies are in clinical trials for various indications.

#### **Example 1 – Treatment of Prostate Cancer**

In this embodiment, hybridoma-producing monoclonal antibodies against NEM are prepared as above. The cDNA encoding the heavy and light chain of the antibody is isolated from the selected hybridoma using standard recombinant DNA techniques. The VH and VL domains of the murine antibody is fused at the DNA level to the human C<sub>k</sub> and C<sub>g</sub> domains (CH1, hinge, CH2 and CH3) of the human antibody again using standard recombinant DNA technology. Grafting loops of the VH and VL domains onto human V domain framework can compensate the loss of affinity sometimes observed with this procedure. The chimeric humanized antibody gene is cloned into a mammalian plasmid vector with a drug selection marker (e.g., neomycin selection marker) and the plasmid transfected into a human myeloma cell line. Stable cell lines producing the chimeric humanized antibodies are selected using the drug selection marker. The recombinant antibody is tested for its cross reactivity with NEM and its ability to inhibit the growth and invasion of prostate cancer cells. Selected myeloma cells are scaled up as mentioned above and the purified antibody is used for the treatment of prostate cancer.

**Example 2 - In-Vitro Production of Human Antibodies Against NEM  
for the Treatment of Prostate Cancer**

In this embodiment, human B cells are grown *in vitro* and NEM is added to the cells in presence of certain ligands like CD40 and human T cell clones. Some of the human B cells immunized *in vitro* can undergo clonal selection and isotype switching. The clones of the B cells producing NEM antibodies with high affinity are selected. The cDNA encoding the antibody is isolated and transfected into human myeloma cells and stable cell lines producing the human antibody against NEM are selected, scaled up and the antibodies purified by methods mentioned above.

**Example 3 - Production of Humanized Antibody in Transgenic Mice**

In this embodiment, NEM, or peptides derived from NEM, are injected in its native form or conjugated to immunogen like keyhole limpet hemocyanin and injected into transgenic mice that carry human V-genes. These mice are defective for the expression of their endogenous (mouse) V genes. This results in the production of antibodies against NEM that utilize the human V genes. The murine B cells that secrete human antibodies are then immortalized by fusing to human myeloma cells using known procedures. The immortalized human myeloma cells producing the human antibodies are scaled up, purified from the cell culture medium, and used for the treatment of prostate cancer.

**Example 4 - Detection of Prostatic NEM in PC Biopsies Using Immunofluorescence**

Prostatic NEM can be detected in PC biopsies by immunofluorescence. The frozen PC specimens are sectioned to 5-10  $\mu$ m size, fixed in Zamboni's fixative and incubated with NEM antiserum for 24 hours at 4°C. The sections are then washed and incubated with anti-rabbit (or mouse) immunoglobulins linked to fluorophores such as FITC, rhodamine, Texas Red or other dyes. The sections are then washed, mounted and observed under the fluorescence microscope with appropriate filters.

**Example 5 - Preparation of Aptamers, Complex Sugars, Organic Compounds and Inorganic Compounds Capable of Binding to Prostatic NEM**

An aptamer is either an RNA, DNA or composed of other modified nucleosides that can bind sequences encoded by cDNA Sequence IDs 2, 3, 4, or 5. A complex sugar molecule, an organic compound or an inorganic compound that can also bind to the peptides of NEM, or its fragments, precursor or homologue. A frozen section of human prostate cancer specimen was

probed with anti-NEM IgG. The antibody was removed, washed and incubated with anti-rabbit IgG-FITC. The presence of NEM-immunopositive cells along the acinar regions was observed.

Serum prostatic NEM can be detected using many known techniques such as radioimmunoassays, fluorescence immunoassays, ELISA, EIA and the like and as generally described in Rose, et al., MANUAL OF CLINICAL LABORATORY IMMUNOLOGY (1997).

#### **Example 6-Radioimmunoassay (RIA)**

Radioactive isotopes can be easily incorporated into NEM and can be easily detected. A radioimmunoassay is a competitive immunoassay where a fixed number of antibody sites are made to react with two sets of antigens (i.e., NEM and NEM\*<sup>3</sup>R-NEM incorporated with a radioisotope). NEM is usually present in variable amounts either in serum samples (unknown amounts) or in standard solutions (where known amounts of NEM are added in variable amounts in series of dilutions). The radioisotope incorporated into NEM is generally either  $I^{125}$ ,  $^3H$  or other molecule. The NEM\*<sup>3</sup>R is added in fixed amounts (as assessed by radioactive counts per minute or cpm,  $NEM+NEM^*R+As-NEM=NEM-As-NEM+NEM^*R-As-NEM$  (radioactivity or cpm)). Since fixed amounts of anti-NEM molecules are made to react with fixed number of NEM\*<sup>3</sup>R molecules and variable numbers of NEM molecules, the resulting concentration of NEM\*<sup>3</sup>R-As-NEM conjugate molecules will be inversely proportional to the concentration of NEM.

The method for conducting NEM RIA comprises: (1) preparing NEM samples; (2) incubating the samples with NEM antiserum; (3) adding NEM\*<sup>3</sup>R; (4) terminating the reaction and precipitating the NEM\*<sup>3</sup>R-As-NEM complexes; and (5) measuring radioactivity and calculation.

##### **1. Preparation of NEM Samples**

The unknown serum NEM samples (e.g., patient serum) needs to be partially purified. Since NEM is a small peptide molecule, NEM\*<sup>3</sup>R can conjugate with various other protein molecules in serum giving rise to very high non-specific binding. The serum samples are precipitated with ethanol acetate, centrifuged and the supernatant is passed through a Sephadex G25 column. The fraction containing NEM are used for the assay.

##### **2. Incubation**

Purified serum samples or standard NEM samples (known amounts of NEM added in the assay buffer) are incubated with anti-NEM serum.

##### **3. Addition**

The NEM\*<sup>3</sup>R (approximately 25,000 cpm) is added to each tube and the incubation is continued.

4. Precipitation and Measurement

After incubation for 24 hours, the NEM-Antibody-NEM complex is precipitated.

The tubes are dried and the pellet is counted for radioactivity. The standard curve is derived by log-logit transformation. The concentrations of NEM in unknown serum samples are calculated from the amount of radioactivity. The sensitivity of the assay is 10-40 pg/tube depending on the stability of NEM\*<sup>R</sup>. As shown in FIG. 8, RIA has been used to measure serum NEM levels in patients with PC.

**Example 7-Enzyme-Linked Immunosorbent Assay (ELISA)**

One or more of the polyclonal antibody, monoclonal antibody, single chain antibody, phage-display antibody, in vitro evolved antibody, and aptamer is conjugated to one or more molecules including, but not limited to, biotin, avidin, fluorescein, rhodamine, alkaline phosphates, horseradish peroxidase and radionuclides such that the conjugate retains its ability to bind prostatic NEM. This conjugate is incubated with serum and the unbound conjugates are removed and the amount of conjugate bound to the NEM is calculated.

**Example 8-Sandwich ELISA**

Sandwich ELISA is an improvement of ELISA that enables one to use unprocessed serum samples for the NEM assay. This eliminates the need for purification of serum samples for the assay and thus improves reliability of the results and simplifies the assay procedure.

Primarily, ELISA plates are coated with the antibody that recognizes one antigenic site of the antigen, which in this case is NEM. Untreated serum samples are added on to wells, and the coated antibody will bind with NEM in the serum samples. Thus, when the samples are washed out with the wash buffer, all other serum components are removed but NEM is retained because of its binding to the coated antibody. Then, a second primary antibody that recognizes another antigenic site of the NEM will react with NEM in proportion to the concentration of NEM. The second antibody is conjugated with a reporter enzyme such as alkaline phosphatase. Therefore, the amount of the antigen can be measured by the color produced on addition of the substrate.

**Example 9-Fluoroimmunoassay (FIA)**

FIA is similar to ELISA but instead of a reporter enzyme, a second antibody is tagged to a fluorophore. Therefore, fluorescence, instead of color reaction, is measured as the end point.

**Example 10-Chemiluminescence Assay**

In the chemiluminescence assay, either NEM or a second antibody is tagged to chemiluminescent compounds such as luciferase or green-fluorescent protein. The light is

measured in a luminometer. A standard curve from NEM concentrations is generated and NEM concentrations of unknown samples are derived from this curve.

#### **Example 11 - Detection of Urine Prostatic NEM**

Prostate cancer patients have been shown to release various prostatic products in urine. Since prostatic tumor cells produce NEM, it may also be released into urine. NEM in urine samples can be analyzed using RIA, ELISA, fluoroimmunoassay or chemiluminescence assay as described above. This process could be used to screen for prostate cancer.

#### **Example 12- In Vivo Detection of PC in Patients Where NEM is Conjugated With a Dye or Radiochemical**

Since NEM should bind to its receptors present on prostate cancer cells, NEM tagged with a dye or a radiochemical can be injected intravenously into a patient and can be tracked to the prostate by imaging devices. Moreover, the radiochemical-NEM conjugate can selectively bind and destroy cancer cells, and can also be used as noninvasive treatment procedure.

Once the prostate cancer has spread to secondary locations, the only treatment currently available for the patient is androgen ablation therapy. However, the tumor becomes insensitive to this therapy after about 12 to 18 months leaving the patient with hardly any treatment choice. However, if one can detect the location of these secondary tumors, they could be surgically removed if such loci are limited in number. There is an intense search for methods to identify sites of secondary metastasis of various cancers. The most promising approach is the use of a targeting molecule akin to a homing devise that can seek out the tumor. Examples of such molecules are antibodies that specifically bind to a protein that is specific for a particular type of cancer. These molecules are conjugated to a radioisotope like Tc-99. The conjugate once injected into the patient seeks out the tumor as a result of the inherent affinity of the targeting molecule for proteins uniquely present on the cancer cells. The location of concentration of the targeting molecule-radioisotope conjugate (location of the tumor) can be identified with a radioactive scanner such as a gamma scanner. Currently, there are no imaging agents for the detection of prostate cancer and NEM may be suitably positioned to fill this void due. Once the secondary tumor sites are identified, they can be excised thereby allowing another treatment option for prostate cancer patients.

In this example, NEM is conjugated to Technetium 99m (Tc99), although several other isotopes are equally useful for tumor imaging. Several procedures for conjugating radioisotope to proteins and peptides are published and several use chelation reagents. The conjugate is injected into the cancer patients. After several hours or days scintigraphs are acquired by gamma cameras.

Scintigraphy is routinely used with different isotopes for the detection of tumors or other lesions. The scintigraphs reveal the site of accumulation of NEM-Tc99 conjugate, which would indicate the location and extent of primary and secondary prostate cancer.

### **Example 13-D-Peptides Blockers of NEM**

NEM binds to its receptors on prostate cancer cells with high affinity (low nM) and initiates biological response. Current pharmacological approaches serve to identify the binding region and biological response regions of a bioactive peptide.

NEM fragments of various sizes are synthesized and used for receptor binding studies as well as for *in vitro* bioassay such as growth of prostate cancer cells. The smallest fragment that retains the receptor binding ability but fails to generate biological response could serve as a competitive antagonist of NEM. Further modifications in the primary structure of the molecule that would increase stability of the peptide, but would not affect its receptor-binding capacity, would lead to the development of antagonists.

The development of an antagonist could provide a therapeutic approach for the treatment of PC, because when administered, the antagonist will occupy NEM receptors but will not generate biological response. In addition, it will prevent the action of locally produced NEM (by blocking its receptors).

Molecules that can block the ability of NEM to bind to its receptors could prevent the growth inducing and spread of prostate cancer cells. Through the use of “mirror image phage display selection” one can select D-peptides that bind to proteins or peptides (e.g. NEM) with high affinity (T.N. Schumacher et. al., SCIENCE, 271:1854 (1996)) and prevent its interaction with its receptor. D-peptides, unlike the natural L-peptides, are not degraded by the peptidases in the body. The technique involves the display of random peptide sequences on a phage filament protein (usually pIII of M13). The phage library is then panned against the target peptide that is chemically synthesized as its D-enantiomer. The phage that binds to the peptide is isolated, amplified in a bacterial host and panned again against the target. After several rounds of selection, the phages that display peptides with high affinity are selected. The sequence of the peptide can be deduced the gene that encodes the filament protein-peptide sequence. An enantiomer of the peptide (mirror image), which is the D form of the peptide, would bind to the L-form of the target peptide.

NEM was synthesized as a D-peptide using conventional peptide synthesis techniques and purified by chromatography. NEM was bound to a plastic petri dish and panned against a phage display library (M13) having 108 individual members. Such libraries are available from

commercial sources (e.g., New England Biolabs, MA). The unbound phage was then washed off and the phage bound to NEM was eluted from the petri dish using mild acid. The eluted phage was then grown in an E.coli host. The phage was again panned against a fresh petri dish coated with NEM. The cycle of binding and elution was repeated 7-8 times until no more enrichment was achieved. The peptide sequence from several isolated phages was determined by PCR sequencing. The deduced peptide sequences were then synthesized as D-peptides and tested for their ability to block NEM-induced growth and invasion in a prostate cancer cell line. Several candidates were tested for their ability to stop tumor growth and invasion in nude mice implanted with human prostate cancer cells. The active sequence was then tested for its toxicity properties in appropriate animal models and then formulated in an aqueous media and administered to prostate cancer patients in clinical trials.

All variants, homologues, mutated variants, alternatively spliced gene variants, pre-mRNA and mRNA molecules of Sequence IDs 2-5 were identified using known techniques. Promoters driving the expression of Sequence IDs 2-5 were also identified.

#### *Detection of Sequence 2*

The expression of the NEM gene can be detected in prostate cancer cells by various techniques such as:

1. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) by synthesizing NEM cDNA-specific amplifiers (from Sequence ID 2) in order to detect the expression of NEM mRNA by RT-PCR.
2. Northern Blot or Slot blot analysis to detect NEM mRNA expression. Total mRNA from the prostate samples is prepared and loaded on to a blot in the slot format or fractionated on denaturing 1% agarose gel and transferred onto nitrocellulose blot, cross-linked and hybridized by a radiolabelled NEM cDNA probe.
3. Preparation of NEM cDNA probe: The probe to detect NEM RNA can be prepared by incorporation of radiochemicals using P<sup>32</sup> or S<sup>35</sup> isotopes, by introducing fluorescence or chemiluminescence tags into the cDNA molecule, or by developing antibodies to the incorporated nucleotide. These antibodies are usually conjugated to gold or reporter enzymes such as alkaline phosphatase or horseradish peroxidase.
4. Ribozyme Amplification.

### **Example 14-Treatment of PC Using Gene Therapy**

Once the factors and mechanisms that regulate NEM gene expression are identified, the factors that suppress NEM gene expression can be used or administered to inhibit endogenous NEM gene expression. An alternative approach is the targeted synthesis of these modulators in PC cells accomplished by producing recombinant retroviruses such as adenovirus driven by prostate-specific promoters such as PSA and contain cDNAs for NEM gene suppressors in their expression cassette. When injected at the site of tumor, the virus invades the tumor site, enters into cells and incorporates into their genome. Because PSA promoter drives its expression, its expression will be selectively induced in prostate cells and other cells such as blood cells, macrophages or cells of connective tissues. Because of the high efficiency of the viral genome, its expression will be high and will produce large amounts of NEM gene suppressors in the tumor area. These suppressors then act on NEM secretors to attenuate NEM synthesis by tumor cells. This approach could provide a clean, targeted and effective treatment for advanced PC.

### **Example 15- Inactivation of NEM RNA Expression Using Antisense and Ribozyme Sequences**

Antisense molecules are gaining importance as tools for specifically inactivating mRNA that code for proteins that are involved in disease processes. Antisense molecules are oligonucleotides that are complementary to a target mRNA. The most commonly used antisense molecules have a DNA backbone, which is stabilized against degradation by endonucleases and exonucleases present in the body by chemical substitution of the phosphate backbone. It is believed that the primary mechanism of antisense action is through endogenous RNase H-mediated cleavage of the RNA at the region of the DNA-RNA hybrid. Improved antisense molecules have a short (7-nucleotide) stretch of DNA flanked by sequences with 2'-substitution. The entire molecule is usually modified in the phosphate backbone to enhance stability. These molecules are more specific and have less toxicity. The backbone substitution of choice is phosphorothioate and the 2' modification includes methyl, ethyl, propyl, methoxyethoxy and allyl.

Since mRNA molecules have very complex tertiary structures, it is impossible to predict which site on a mRNA would be accessible for binding of the antisense molecule. Current methods of determining such accessible sites are random and involve synthesis of a large number of antisense molecules and testing their activity in cells. Once an antisense molecule has been

identified that has proper antisense activity and limited toxicity, large amounts of the molecule are synthesized and administered as an intravenous infusion.

Another mode of inactivation of mRNA coding for a protein is through the use of ribozymes, which are molecules that can cleave mRNA. Ribozymes can be designed to cleave specific mRNA by introducing sequences that are complementary to the target mRNA. This would allow the ribozymes to specifically bind to the target mRNA and inactivate it. Ribozymes can be chemically synthesized and administered like a conventional drug or can be expressed in appropriate tissues using viral vectors. In the former case, the molecules are stabilized against nuclease degradation by introducing appropriate chemical substitutions in the molecule.

Triplex molecules bind to the major grove of the DNA usually in the purine rich region and prevent the transcription of the mRNA coding for the protein of interest.

Several 21 nucleotide antisense molecules are synthesized using a standard DNA synthesizer. These molecules are composed of a 7-nucleotide DNA sequence in the middle and two 7 nucleotides 2' O-methyl RNA sequences flanking the central DNA portion. The entire molecule is modified in the phosphate backbone with sulfur substitution (phosphorothioate backbone). Forty sequences complementary to different regions of NEM mRNA are synthesized and purified by reverse phase HPLC method.

The antisense molecules are added to PC-3M cells growing in culture and the ability of the antisense to block growth and invasion and its ability to reduce NEM mRNA are monitored. The more active and least toxic (as measured by cellular toxicity assays) sequences are scaled up and tested in nude mice baring prostate tumor to test the efficacy of the antisense molecule to stop the tumor growth and spread. The best candidate is selected, scaled up and administered as an intravenous infusion in prostate cancer patients to determine the efficacy of these molecules in preventing the growth and spread of prostate cancer.

#### **Example 16-Preparation of Prostatic NEM Antagonist-Antineoplastic Conjugates**

Compositions to treat prostate cancer are produced using known techniques wherein NEM or NEM antibodies are conjugated to chemotherapeutic agents such as Paclitaxel, Cladribine, Pentostatin, Fludarabine, Carboplatin, Isofamide, Octreotide acetate, Mitoxantrone, Streptozocin, Stophoside, Flutamide, Leuprolide, Tamoxifen, Bleomycin, Doxorubicin, Cisplatin, Dacabazine, Daunorubicin, Nitrosoureas, Mithramycin, Cytarabine, Procarbazine, Hydrozyurea, Mitomycin C, Vinca alkaloids, Mitotane, Cyclophosphamide, Progestins, 5-Fluorouracil, Actinomycin D, 6-

mercaptopurine, and the like. These compositions are made into a pharmaceutically acceptable form for human administration.

**Example 17-Preparation of Prostatic NEM Antagonist-Radionuclide Conjugates**

Compositions to treat prostate cancer are produced using known techniques wherein the above-described NEM immunogens are conjugated to radionuclides such as Ac-225, Ac-227, Au-198, B-11, Bi-212, Bi-213, Br-77, Cf-252, Co-60, Cs-137, Cu-67, Ir-192, Os-194, Pb-203, Pb-212, Pd-103, Pd-109, Ra-223, Ra-226, Re-186, Re-188, Rh-105, Sc-47, Si-28, Sm-145, Sr-89, Sr-90, Ta-182, Tb-149, Th-228, Th-229, W-188, Y-88, Y-90, Y-91, and the like. The compositions are made into a pharmaceutically acceptable form for human administration. As illustrated in Fig. 11, such cell-targeted therapy is employed to selectively kill cancer cells.

**Example 18-Preparation of Prostatic NEM-Antineoplastic and NEM-Radionuclide Conjugates**

This cancer treatment composition is a combination of the above wherein a chemotherapeutic agent and a radionuclide are conjugated to an NEM immunogen and then administered to the patient.

All references cited in this application are hereby incorporated by reference.

While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations in the preferred methods of the present invention may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents encompassed with the spirit and scope of the invention as defined by the following claims.

**SEQUENCE LISTING**

(1) GENERAL INFORMATION:

(i) APPLICANT: Shah, Girish V.

(ii) TITLE OF INVENTION: Neuroendocrine Marker of Prostate Cancer and Method for Producing Same

(iii) NUMBER OF SEQUENCES: 12

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Sonnenschein Nath & Rosenthal
- (B) STREET: 8000 Sears Tower
- (C) CITY: Chicago
- (D) STATE: Illinois
- (E) COUNTRY: USA
- (F) ZIP: 60606

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE:
- (B) COMPUTER:
- (C) OPERATING SYSTEM:
- (D) SOFTWARE:

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: N.A.
- (B) FILING DATE:
- (C) CLASSIFICATION: N.A.

(vii) PRIOR APPLICATION DATE: N.A.

(2) INFORMATION FOR SEQUENCE ID NO: 1

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 Amino Acids
- (B) TYPE: Amino Acid
- (C) STRANDEDNESS: N.A.
- (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1

Cys	Ser	Val	Lys	Ser	Thr	Ser	Cys	Val	Ser
Lys	Val	Lys	Phe	His	Phe	Asn	His	Met	Gln
Asp	Ile	Pro	Gln	Arg	Tyr	Arg	Gln	Val	Asp
Cys	Ile	Phe	Phe	Leu	Phe	Ser	Phe	Ser	Phe
Phe	Ser	Glu	Leu	Gly	Thr	Glu	Pro		

(2) INFORMATION FOR SEQUENCE ID NO: 2

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 691 Base Pairs
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQUENCE ID NO: 2

10	20	30	40	50	60
AGAACCTGTG TGCTGGGCTA CCTGCATATA GTGCTCAGTA CTGAGTACTA GCTGTGTTTC					
70	80	90	100	110	120
CTTAGTCCTG TTTCACTTA ACCATATGCA AGACATTCT CAACGTTATA GGCAAGTAGA					
130	140	150	160	170	180
CTGCATCTT TTTCTTTTTT CTTTTCTTT TTTCTCGGAG CTGGGGACCG AACCCAGGAC					
190	200	210	220	230	240
CTTGCCTTG CTAGGCCASN CNTNACCACT GAGCTAAATC CCCAACCCCCG ACTGCATCGT					
250	260	270	280	290	300
TTTTGGTTTT TAGTAAATT CCGGTTTGCT CTATTCGTG TTCCCTTGT TTAAAAGAAA					
310	320	330	340	350	360
CTGTAGCCGG GGTAGTATAT GTCTATAATC CCAGCAGTTG GGAGGCAGGA GGATCCAGAG					
370	380	390	400	410	420
TTCAAGTCGG CATGGAACAC ATGAGACATT AGCTAAAAAA AAAAAAAA AAAAGTCGAC					
430	440	450	460	470	480
TGAGAATTCC ACAATCCCGC GGCCATGGCG GCGGGAGCA TGCGACGTCG GGCCCAATT					
490	500	510	520	530	540
GCCCTATAGT GAGTCGTATT ACAATTCACT GGCGTCGTT TTTACAACGT CGTGACTGGG					
550	560	570	580	590	600
AAAACCCTGG CGTTACCCAA CTTAATCGCT TGCAGCACAT CCCCTTCGC AGCTGGCTAA					
610	620	630	640	650	660
TAGCGAGAGG CCCGCACCGA TCGCCCTCCC AACAGTTGCG CACCGGAATN GCGAATGGAC					

670

680

690

GCGCCCTGTA GCGNCATTAA GGGCGNGTGT G

## WHAT IS CLAIMED IS:

1. A cDNA sequence encoding a peptide produced and secreted by human prostate cancer cells and prostate cancer tissue, the cDNA sequence having substantial homology with a cDNA sequence selected from the group consisting of Sequence ID 2, Sequence ID 3, Sequence ID 4, and Sequence ID 5.
2. A peptide encoded by the cDNA sequence according to Claim 1, the peptide having substantial homology with a peptide selected from the group consisting of Sequence ID 1, Sequence ID 6, Sequence ID 7, Sequence ID 8, Sequence ID 9, Sequence ID 10, Sequence ID 11, and Sequence ID 12.
3. A composition comprising, the peptide of Claim 2, conjugated with at least two members selected from the group consisting of monoclonal antibodies, single chain antibodies, phage-display evolved antibodies, in-vitro evolved antibodies and aptamers, the at least two members bound to different epitopes of the peptide such that binding of the first member does not compromise binding of the second member.
4. A method for delivering at least one of a detectable label or cytotoxic agent to prostate cancer cells in humans comprising the steps of administering the peptide of Claim 2, conjugated with a detectable label or a cytotoxic agent, to a patient, and detecting the presence or absence of the detectable label in the patient, or treating the cancer cells.
5. A composition for treating prostate cancer, comprising the peptide of Claim 2, conjugated with a binding agent capable of inhibiting binding of the peptide to its receptor, thereby inhibiting an ability of the peptide to induce prostate cancer cell growth, the binding agent being selected from the group consisting of:
  - (a) an antibody selected from the group of monoclonal antibodies, partially or fully humanized monoclonal antibodies, polyclonal antibodies, antibodies selected by phage display selection, single chain antibodies, in-vitro-evolved antibodies or a synthetic antibodies capable of binding to the peptide;

- (b) a D-peptide sequence selected by mirror image phage display selection and capable of binding to the peptide;
- (c) a peptidomimetic compound capable of inhibiting binding of the peptide to prostate cancer cells;
- (d) an aptamer comprising DNA, RNA or other modified nucleoside analogs.

## **ABSTRACT**

The present invention involves a novel neuroendocrine growth factor or marker (“NEM”) identified in cultured prostate cancer cells and conjugates of NEM and a binding agent capable of inhibiting binding of NEM to its receptor.




FIG. 1




FIG. 2




FIG. 3




FIG. 4



PIN 1

a



Moderate Grade 1

b



High Grade 1

c

FIG. 5





FIG. 6




Liver Metastasis

a



Lymph Node Metastasis

b



Tonsils (negative control)

c

FIG. 7






FIG. 8

# NUINDUCED PROLIFERATION OF PROSTATE CANCER CELLS

FIG. 9




## Fig. 10 PROPOSED MECHANISM OF NEM-MEDIATED PROLIFERATION AND INVASION OF PROSTATE CANCER CELLS




Normal prostate cells produce very little or no NEM and possess very little or no NEM receptor

Prostate cancer cells produce and secrete NEM (red bullet). These cells also express NEM receptors (specific proteins to which NEM must bind in order to mediate its action) on the surface of cells (Y shaped molecule)




NEM binds to NEM receptors on prostate cancer cells (like a lock and key) thereby stimulating cell division and invasion




Prostate cancer cells divide and invade (metastasize)



## Fig.1: NEM-BASED CELL-TARGETED RADIATION THERAPY



NEM-radioisotope conjugate binds to NEM receptors present on cancer cell surface.  
Radioisotope emits radiation in close proximity to cancer cell.




NEM-radioisotope conjugate would not bind to non-prostate cells present in other organs - non prostate cells spared


Prostate cancer cells are killed by radiation



## Fig.12: NEM ANTIBODY-BASED THERAPEUTIC FOR TREATMENT OF PROSTATE CANCER




**Fig. 13 NEM SELECTIVELY BINDS TO PROSTATE CANCER CELLS**  
(Increased expression of NEM receptor in prostate cancer cells)



*A section of a prostate cancer tissue showing NEM selectively binding to NEM receptor present on prostate cancer cells. Cells with NEM bound to them (cancer cells) are stained dark brown (wide band of cells on right abutting normal cells (pink) on the left. NEM is conjugated to a detection tag (digoxigenin- alkaline phosphatase) in order to visualize its binding to cancer cells. The data demonstrates the ability of NEM to direct itself to cancer cells and bind to them selectively. In the prostate cancer-imaging agent, one merely replaces the digoxigenin tag with a radioisotope like In-111. NEM would direct In-111 to prostate cancer cells wherever they are present in the body. The sites of accumulation of NEM-In-111 (sites of tumor) can be detected using a gamma camera. (The large dark blue spots are artifacts of the video camera).*

## IMMUNOHISTOCHEMICAL DETECTION OF NEM IN PROSTATE CANCER TISSUE SECTIONS

*Note: Areas stained blue are cells that produce NEM – cancer cells.*




High-grade PIN, a precursor of invasive cancer.



Moderate-grade cancer.




High-grade cancer. Left portion is cancer tissue and the right portion is normal. Only the cancer tissue produces NEM (stained blue)



Aggressive cancer. The cancer cells (intense blue) grow haphazardly.

*Immunohistochemistry stains for the presence of NEM peptide in cancer tissue. An antibody against NEM binds selectively to NEM, which is then detected by secondary reagents, which stains the tissue blue.*

## DETECTION OF NEM IN SECONDARY SITES OF PROSTATE CANCER *In situ* hybridization




Section of a liver tissue showing a small prostate cancer secondary nodule. The cancer cells (in the middle) produce NEM (stained dark) while the surrounding liver tissue (stained pink) does not. This is a clear demonstration of the prostate cancer-specific nature of NEM

Fig. 14

**Fig. 15 EXPRESSION OF NEM IN BPH AND PROSTATE CANCER TISSUES SECTIONS**  
*In situ* hybridization.


*Areas stained dark indicate cells producing NEM –note increased production of NEM with increasing grade of cancer – the more aggressive the cancer more the production of NEM. High-grade PIN is a precursor of invasive cancer. BPH (benign prostatic hyperplasia) or prostate enlargement is a non-cancerous condition. Note loss of architecture of prostate tissue with advancing cancer. The cancer usually grows as small glands with the cancer cells lining the glands (see moderate grade cancer). In high-grade cancer, the glandular shape is lost and the cells grow in a haphazard fashion.*




BPH (enlarged prostate)  
No expression of NEM




High-grade PIN (pre-cancerous lesion). Some moderate-grade cancer can also be seen




Moderate-grade cancer. Cancer cells line the small glands. Higher magnification



Moderate-grade cancer (note large number of small glands)



High-grade cancer



Aggressive cancer

*The levels of NEM expression in prostate tissue is estimated by determining the level of NEM mRNA using NEM-specific probes and reagents, which stains cells expressing NEM.*

Fig. 15

DNASIS

\*\*\*\*\* DNA TRANSLATION LIST \*\*\*\*\*

DATE 02-13-99

SEQUENCE 3 : 1-433

\*\*\* DNA TRANSLATION \*\*\*

10 20 30 40 50 60  
 5'AGAACCTGTGTGCTGGGCTACCTGCATATAGTGCCAGAGTTCATCGAATCTCAGCTGCTG  
 SEQ 6 → R T C V L G Y L H I V P E F I E S Q L L  
 SEQ 7 → E P V C W A T C I \* C Q S S S N L S C W  
 SEQ 8 → N L C A G L P A Y S A R V H R I S A A G

70 80 90 100 110 120  
 GGGCTCCTAGTCCTGTTTCACTTAACCATATGCAAGACATTCTCAACGTTATAGGCA  
 G L L S P V S L \* P Y A R H S S T L \* A  
 G S L V L F H F N H M Q D I P Q R Y R Q  
 A P \* S C F T L T I C K T F L N V I G K

130 140 150 160 170 180  
 AGTAGACTGCATTTTTTTCTTTCTTTCTTTCTTTCTTTCTTTCTGGAGCT  
 S R L H L F F S F F F F F F L F F G A  
 V D C I F F F L F F S F S F F F F S E L  
 \* T A S F F F F F L F L F S F F R S W

190 200 210 220 230 240  
 GGGGACCGAACCCAGGACCTTGCCTTGCTAGGCAAGCGCTCTACCACTGAGCTAAATCC  
 G D R T Q D L A L A R Q A L Y H \* A K S  
 G T E P R T L R L L G K R S T T E L N P  
 G P N P G P C A C \* A S A L P L S \* I P

250 260 270 280 290 300  
 CCAACCCCGACTGCATCGTTGGTTTTAGTTAAATTCCGGTTGCTCTATTCGTGT  
 P T P T A S F L V F S \* I P V C S I S C  
 Q P R L H R F W F L V K F R F A L F R V  
 N P D C I V F G F \* L N S G L L Y F V F

310 320 330 340 350 360  
 TCCCTTTGTTAAAAAGAAAATGTAGCCGGGGTAGTATATGTCTATAATCCCAGCAGTTGG  
 S L C L K E T V A G V V Y V Y N P S S W  
 P F V \* K K L \* P G \* Y M S I I P A V G  
 P L F K R N C S R G S I C L \* S Q Q L G

370 380 390 400 410 420  
 GAGGCAGGAGGATCCAGAGTTCAAGTCGGCATGGCACACATGAGACATTAGCTAAAAAA  
 E A G G S R V Q V G M A H M R H \* L K K  
 R Q E D P E F K S A W H T \* D I S S K K  
 G R R I Q S S S R H G T H E T L A Q K K

430  
 AAAAAAAA 3'  
 K K K K  
 K K K K

Fig. 16

DNASIS

\*\*\*\*\* DNA TRANSLATION LIST \*\*\*\*\*

DATE 02-13-99

SEQUENCE 3 : 1-433

\*\*\* DNA TRANSLATION \*\*\*

5' AGAACCTGTGTGCTGGGCTACCTGCATATAGTGCCAGAGTTCATCGAATCTCAGCTGCTG  
GGGCTCCTAGTCCTGTTCACTTAACCATATGCAAGACATTCTAACGTTATAGGCA  
AGTAGACTGCATCTTTTTTTCTTTTTCTTTCTTTTTCTTTTCGGAGCT  
GGGGACCGAACCCAGGACCTTGCCTTGCTAGGCAAGCGCTCTACCACTGAGCTAAATCC  
CCAACCCCGACTGCATCGTTTGGTTTTAGTTAAATTCCGGTTGCTCTATTCGTGT  
TCCCTTTGTTAAAAGAAACTGTAGCCGGGTAGTATATGTCTATAATCCCAGCAGTTGG  
GAGGCAGGAGGATCCAGAGTTCAAGTCGGCATGGCACACATGAGACATTAGCTAAAAAA  
AAAAAAAAAAAAA 3'

Fig. 16 Cont

SEQUENCE 4 : 1-432

## \*\*\* DNA TRANSLATION \*\*\*

10 20 30 40 50 60

5' AGAACCTGTGTGCTGGCTACCTGCATATAGTGCCAGAGTTCATCGAATCTCAGCTGCTG  
 SEQ 9 → R T C V L G Y L H I V P E F I E S Q L L  
 SEQ 10 → E P V C W A T C I \* C Q S S S N L S C W  
 SEQ 11 → N L C A G L P A Y S A R V H R I S A A G

70 80 90 100 110 120

GGGCTCCTAGTCCTGTTCTTAAACCATATGCAAGACATTCTCAACGTTATAGGCAA  
 G L L S P V S F N H M Q D I P Q R Y R Q  
 G S L V L F P L T I C K T F L N V I G K  
 A P \* S C F L \* P Y A R H S S T L \* A S

130 140 150 160 170 180

GTAGACTGCATCTTTTTTTCTTTCTTTCTTTCTTTCTTTCTGGAGCTG  
 V D C I F F F L F F S F S F F F F S E L  
 \* T A S F F F F F L F L F S F F R S W  
 R L H L F F S F F F F F L F F G A G

190 200 210 220 230 240

GGGACCGAACCCAGGACCTTGCCTGCTAGGCAAGCGCTCTACCACTGAGCTAAATCCC  
 G T E P R T L R L L G K R S T T E L N P  
 G P N P G P C A C \* A S A L P L S \* I P  
 D R T Q D L A L A R Q A L Y H \* A K S P

250 260 270 280 290 300

CAACCCCGACTGCATCGTTGGTTTTAGTTAAATCCGGTTGCTCTATTCGTGTT  
 Q P R L H R F W F L V K F R F A L F R V  
 N P D C I V F G F \* L N S G L L Y F V F  
 T P T A S F L V F S \* I P V C S I S C S

310 320 330 340 350 360

CCCTTGTTAAAAGAAACTGTAGCCGGGGTAGTATGTCTATAATCCAGCAGTTGGG  
 P F V \* K K L \* P G \* Y M S I I P A V G  
 P L F K R N C S R G S I C L \* S Q Q L G  
 L C L K E T V A G V V Y V Y N P S S W E

370 380 390 400 410 420

AGGCAGGAGGATCCAGAGTTCAAGTCGGCATGGCACACATGAGACATTAGCTAAAAAA  
 R Q E D P E F K S A W H T \* D I S S K K  
 G R R I Q S S S R H G T H E T L A Q K K  
 A G G S R V Q V G M A H M R H \* L K K K

430

AAAAAAA 3'  
 K K K K  
 K K K

Fig. 17

DNASIS

\*\*\*\*\* DNA TRANSLATION LIST \*\*\*\*\*

DATE 02-13-99

SEQUENCE 4 : 1-432

5' AGAACCTGTGTGCTGGCTACCTGCATATAGTGCCAGAGTTCATCGAATCTCAGCTGCTG  
GGGCTCCTTAGTCCTGTTCTTAACCATATGCAAGACATTCTAACGTTATAGGCAA  
GTAGACTGCATCTTTTTTTCTTTTCTTTCTTTTCTGGAGCTG  
GGGACCGAACCCAGGACCTTGCCTGCTAGGCAAGCGCTCTACCACTGAGCTAAATCCC  
CAACCCCGACTGCATGTTGGTTAGTTAAATTCCGGTTGCTCTATTCGTGTT  
CCCTTGTTAAAAGAAACTGTAGCCGGGTAGTATATGTCTATAATCCCAGCAGTTGGG  
AGGCAGGAGGATCCAGAGTTCAAGTCGGCATGGCACACATGAGACATTAGCTCAAAAAAA  
AAAAAAAAAAA 3'

FIG.17 Cont

# Sequence 5

NEM DNA SEQUENCE 1-435

ATTAGAACCT GTGTGCTGGG CTACCTGCAT ATAGTGCAG AGTTCATCGA ATCTCAGCTG CTGGGGCTCC  
TTAGTCCTGT TTCCCTTAAC CATATGCAAG ACATTCTCA ACGTTATAGG CAAGTAGACT GCATCTTTT  
TTTTCTTTT TTTTCTTTT CTTTTCTTCTT TTTTCGGAG CTGGGGACCG AACCCAGGAC CTTGCGCTTG  
CTAGGCAAGC GCTCTACAC TGAGCTAAAT CCCCAACCCC GACTGCATCG TTTTTGGTTT TTAGTTAAAT  
TCCGGTTTGC TCTATTCGT GTTCCCTTG TTTAAAAGAA ACTGTAGCCG GGGTAGTATA TGTCTATAAT  
CCCAGCAGTT GGGAGGCAGG AGGATCCAGA GTTCAAGTCG GCATGGCACA CATGAGACAT TAGCTCAAAA

AAAAAAAAA AAAAA

FIG. 18

NEM PEPTIDE SEQUENCE

12

Ile Arg Thr Cys Val Leu Gly Tyr Leu His Ile Val Pro Glu Phe Ile Glu Ser  
Gln Leu Leu Gly Leu Leu Ser Pro Val Ser Leu

FIG.19